Voxilaprevir

Major

Voxilaprevir Abametapir Explained Increased exposure of CYP3A4 substrate Details Voxilaprevir Relugolix Orgovyx Explained Increased relugolix exposure Details Voxilaprevir Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Voxilaprevir Atogepant Qulipta Increased atogepant exposure Details Voxilaprevir Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Voxilaprevir Cyclosporine Injection Atopica Increased voxilaprevir plasma concentrations Details Voxilaprevir Cyclosporine Ophthalmic Cequa Increased voxilaprevir plasma concentrations Details Voxilaprevir Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Voxilaprevir Dexamethasone Injection Decadron Reduced voxilaprevir exposure Details Voxilaprevir Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced voxilaprevir exposure Details Voxilaprevir Digoxin Cardoxin® Increased digoxin exposure Details Voxilaprevir Fostemsavir Rukobia Possible increase in plasma concentrations of voxilaprevir Details Voxilaprevir Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Voxilaprevir Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Voxilaprevir Leniolisib Joenja Increased OATP1B1/OATP1B3 substrate exposure Details Voxilaprevir Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Voxilaprevir Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Voxilaprevir Nafcillin Injection Unipen® Injection Reduced voxilaprevir exposure Details Voxilaprevir Nevirapine Viramune Reduced voxilaprevir exposure Details

Moderate

Voxilaprevir Simvastatin Flolipid Explained Increased plasma concentrations of the HMG-CoA reductase inhibitor Details Voxilaprevir Atorvastatin Atorvaliq Increased plasma concentrations of the HMG-CoA reductase inhibitor Details Voxilaprevir Encorafenib Braftovi Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Voxilaprevir Fluvastatin Lescol Increased plasma concentrations of the HMG-CoA reductase inhibitor Details Voxilaprevir Lovastatin Altocor® Increased plasma concentrations of the HMG-CoA reductase inhibitor Details